Bangladesh | BCH-NR5-BD-287690 | Fifth National Report on the Implementation of the Cartagena Protocol on Biosafety

Article 2 – General provisions

Article 2 requires each Party to take the necessary and appropriate legal, administrative and other measures to implement its obligations under the Protocol

7. Has your country introduced the necessary national measures for the implementation of the Protocol?

National measures are fully in place

EN

8. Which specific instruments are in place for the implementation of national biosafety measures? (select all that apply)

One or more national biosafety laws
One or more national biosafety regulations
One or more sets of biosafety guidelines
Other laws, regulations or guidelines that indirectly apply to biosafety

Please provide further information on the instruments in place:

Bangladesh has both sectoral and cross-sectoral policies addressing biosafety measures, such as the National Biotechnology Policy 2012 and the National Environment Policy 2018.

EN

9. Has your country integrated biosafety in national sectoral and cross-sectoral strategies, action plans, programmes, policies or legislation?

Yes, to some extent:

EN

Additional Information

The Biosafety policy 2024, National Environment Policy 2018 and Bangladesh Biotechnology Policy, 2012 have the elements on biosafety to be ensured in the research and development on modern biotechnology.

EN

10. Does your country have resources for biosafety from national budgets?

Yes

EN

Are these resources adequate:

No

EN

11. Does your country have qualified staff to administer functions directly related to biosafety?

Yes

EN

12. If you answered Yes to question 11, how many qualified staff members are in place whose functions are directly related to biosafety?

10 or more

EN

Is this number adequate:

No

EN

13. Please use the space below to provide further details on the implementation of Article 2 in your country:

Bangladesh has established a robust regulatory framework for biosafety over the past two decades. Following the development of the National Biosafety Framework (NBF) in 2007, the government published the Biosafety Guidelines of Bangladesh in 2008, which were later incorporated into the Bangladesh Biosafety Rules (2012). To strengthen technical oversight, the Environmental Risk Assessment Guidelines were gazetted in 2016. Furthermore, the National Environment Policy (2018) and the Bangladesh Biotechnology Policy (2012) mandate strict biosafety standards for biotechnology research and development. Most recently, the government introduced the Biosafety Policy of Bangladesh (2024).

EN

Article 5 – Pharmaceuticals

14. Does your country regulate the transboundary movement, handling or use of living modified organisms (LMOs) which are pharmaceuticals for humans?

No

EN

15. Please use the space below to provide further details on the implementation of Article 5 in your country:

Bangladesh implements Article 5 by excluding LMO-based pharmaceuticals for humans from its biosafety regulatory scope as they are managed under alternative international health standards. In Bangladesh, the Directorate General of Drug Administration (DGDA) oversees the handling and transboundary movement of such products under established national health and drug policies.

EN

Article 6 – Transit and contained use

16. Does your country regulate the transit of LMOs?

Yes

EN

17. Does your country regulate the contained use of LMOs?

Yes

EN

18. Has your country taken a decision concerning the import of LMOs for contained use?

Yes

EN

19. Please use the space below to provide further details on the implementation of Article 6 in your country:

Bangladesh has approved the Late blight resistance 3R gene enriched Potato for the Contained Test at Bangladesh Agriculture Research Institute (BARI). Origin of gene: Rpi-blb2 from Solanum bulbacastanum, Rpi-vntl from Solanum venturi and Rpi-mcql from Solanum mochiquense.

EN

Articles 7 to 10: Advance informed agreement (AIA) and intentional introduction of LMOs into the environment

20. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?

Yes

EN

21. Has your country established legal requirements for the accuracy of information contained in the notification provided by exporters under its jurisdiction?

Yes

EN

22. In the current reporting period, has your country received a notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?

Yes

EN

23. If you answered Yes to question 22, did the notification(s) contain complete information (at a minimum the information specified in Annex I to the Cartagena Protocol on Biosafety)?

Yes, always

EN

24. If you answered Yes to question 22, has your country acknowledged receipt of the notification(s) to the notifier within ninety days of receipt?

In some cases only

EN

25. If you answered Yes to question 22, has your country informed the following of its decision(s):

a. The notifier?

Yes, always

EN

b. The Biosafety Clearing-House (BCH)?

No

EN

26. In the current reporting period, has your country taken a decision in response to the notification(s) regarding intentional transboundary movements of LMOs for intentional introduction into the environment?

Yes

EN

Please specify how many

1

EN

27. If you answered Yes to question 26, what percentage of your country’s decisions fall into the following categories?

Approval of the import/use of the LMO(s) with conditions (100)

Were the reasons for the conditions provided?

Yes, always

EN

Were the reasons for the prohibition provided?

28. If you answered Yes to question 26, how many LMOs has your country approved for import for intentional introduction into the environment?

1 to 4

EN

29. If you answered under question 28 that LMOs were approved, have these LMOs actually been imported into your country?

Yes, always

EN

30. Please use the space below to provide further details on the implementation of Articles 7 to 10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:

Bangladesh implements the Cartagena Protocol through a multi-tiered regulatory process defined by the Biosafety Rules (2012) and Guidelines (2008). During the reporting period, a notable achievement in this framework was the approval of two Bt cotton varieties (JKCH 1947 and JKCH 1050) for commercial cultivation in 2023. This introduction followed a thorough assessment and a gradual transition from greenhouse trials to multi-location field tests.

EN

Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)

31. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?

Yes

EN

32. Has your country established legal requirements for the accuracy of information to be provided by the applicant regarding the domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?

Yes

EN

33. In the current reporting period, how many decisions has your country taken regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?

None

EN

34. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding the import of LMOs for direct use as food or feed, or for processing?

Yes

EN

35. In the current reporting period, how many decisions has your country taken regarding the import of LMOs for direct use as food or feed, or for processing?

None

EN

36. Please use the space below to provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing:

Bangladesh enforces Article 11 through the Biosafety Rules (2012) and Guidelines (2008), requiring prior approval for all LMOs-FFP from the National Committee on Biosafety (NCB). The decision-making process follows the precautionary principle, as detailed in Section 3.2.2.3 of the Guidelines. This means that uncertainty regarding potential adverse effects does not preclude action to mitigate risks to biological diversity and human health. While no final decisions on LMOs-FFP were taken during this reporting period, the framework is active. Importers are required to provide a certificate from the exporting country confirming the products are "fit for human consumption," free from harmful ingredients/germs.

EN

Article 12 – Review of decisions

37. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?

Yes

EN

38. In the current reporting period, has your country reviewed and/or changed a decision regarding an intentional transboundary movement of an LMO?

No

EN

39. If you answered Yes to question 38, how many decisions were reviewed and/or changed?

40. If you answered Yes to question 38, were any of the reviews triggered by a request from the Party of export or the notifier?

41. If you answered Yes to question 40, did your country provide a response within ninety days setting out the reasons for the decision?

42. If you answered Yes to question 38, were any of the reviews initiated by your country as the Party of import?

43. If you answered Yes to question 42, did your country, within thirty days, set out the reasons for the decision and inform:

a. The notifier?

b. The BCH?

44. Please use the space below to provide further details on the implementation of Article 12 in your country:

The mechanism for review is established under Rule 12 of the Biosafety Rules (2012). It provides a time-bound administrative remedy for any “aggrieved person” affected by decisions regarding the import, export, or commercial use of LMOs. While no reviews were formally undertaken in this reporting period, the legal framework is in place to allow for such a process, ensuring transparency and accountability in decision-making.

EN

Article 13 – Simplified procedure

45. Has your country established a mechanism for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?

Yes

EN

46. In the current reporting period, has your country applied the simplified procedure?

No

EN

47. If you answered Yes to question 46, for how many LMOs has your country applied the simplified procedure?

48. If you answered Yes to question 46, has your country informed the Parties through the BCH of the cases where the simplified procedure was applied?

49. Please use the space below to provide further details on the implementation of Article 13 in your country:

To date, Bangladesh has not formally applied a simplified procedure for any intentional transboundary movement of LMOs.

EN

Article 14 – Bilateral, regional and multilateral agreements and arrangements

50. How many bilateral, regional or multilateral agreements or arrangements relevant to biosafety has your country established with other Parties/non-Parties?

1 to 4

EN

51. If you answered under question 50 that agreements or arrangements were established, please provide a brief description of their scope and objective:

A subaward agreement was signed on February 9, 2023 between the Bangladesh Agricultural Research Institute and Michigan State University, USA, under USAID to develop late blight-resistant potato incorporating three resistance (3R) genes, covering genetic development, biosafety evaluation, confined testing, and regulatory data generation. However, USAID funding was discontinued in January 2025.

EN

52. Please use the space below to provide further details on the implementation of Article 14 in your country:

Bangladesh has few formal bilateral or multilateral agreements with parties and maintain regular communication with our regional counterparts. We invite expert scientists from neighbouring countries to participate in our meetings and workshops related to biosafety, either as resource persons or participants. Additionally, we take part in biosafety-related meetings organized by our counterparts.

EN

Articles 15 & 16 – Risk assessment and risk management

53. Does the domestic regulatory framework of your country require risk assessments of LMOs to be conducted?

Yes

EN

To which LMOs does this requirement apply (select all that apply):

For imports of LMOs for intentional introduction into the environment
For imports of LMOs intended for direct use as food or feed, or for processing
For decisions regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movements for direct use as food or feed, or for processing
For imports of LMOs for contained use

54. Has your country established a mechanism to conduct risk assessments prior to taking decisions regarding LMOs?

Yes

EN

Conducting risk assessment or risk management

55. In the current reporting period, has your country conducted any kind of risk assessment of LMOs, including for contained use, field trials, commercial purposes, direct use as food, feed, or for processing?

Yes

EN

56. If you answered Yes to question 55, how many risk assessments were conducted?

1 to 9

EN

57. If you answered Yes to question 55, please indicate the scope of the risk assessments (select all that apply):

LMOs for contained use (in accordance with Article 3)
LMOs for intentional introduction into the environment for experimental testing or field trials
LMOs for intentional introduction into the environment for commercial purposes

58. If you answered Yes to question 55, were risk assessments conducted for all decisions taken on LMOs for intentional introduction into the environment or on domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?

Yes, always

EN

59. If you answered Yes to question 55, have you considered:

a. other available scientific evidence, as referred to in Article 15 of the Protocol?

Yes, in all cases

EN

b. relevant traditional knowledge of indigenous peoples and local communities?

In some cases

EN

60. If you answered Yes or In some cases to question 59(b), was this information considered in a scientifically sound manner?

Yes

EN

61. Has your country established appropriate mechanisms, measures and strategies to regulate and manage risks identified in the risk assessment of LMOs?

Yes

EN

62. Has your country taken appropriate measures to prevent unintentional transboundary movements of LMOs including such measures as requiring a risk assessment to be carried out prior to the first release of a LMO? ¹

Yes, to some extent:

EN

63. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?

Yes

EN

64. Has your country established a mechanism for monitoring potential effects of LMOs released into the environment?

Yes, to some extent:

EN

Additional Information

Through the Field Level Biosafety Committee (FBC). Conditions for commercial release, like that for Bt cotton, include a monitoring plan for insect resistance management and general surveillance.

EN

65. Does your country have measures to identify LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?

Yes

EN

66. Has your country had access to or used any resource materials, including guidance documents, for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?

a. Risk assessment:

Yes

EN

b. Risk management:

Yes

EN

67. If you answered Yes to question 66(a) or (b), is your country using the “Guidance on Risk Assessment of LMOs” (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) ² for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?

Yes

EN

68. Does your country have specific needs for further guidance on specific topics of risk assessment of LMOs?

Yes

EN

Additional Information

Bangladesh needs further guidance on specific topics of risk assessment case-by-case and risk management, long-term environmental impacts.

EN

Capacity-building in risk assessment or risk management

69. Does your country have the capacity to detect, identify, assess the risk of and/or monitor LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?

a. Detect:

Yes

EN

b. Identify:

Yes

EN

c. Assess the risk:

Yes

EN

d. Monitor:

Yes

EN

70. In the current reporting period, how many people in your country have been trained in risk assessment, risk management and monitoring of LMOs?

a. Risk assessment:

10 to 49

EN

Is this number adequate:

No

EN

b. Risk management:

10 to 49

EN

Is this number adequate:

No

EN

c. Monitoring:

10 to 49

EN

Is this number adequate:

No

EN

71. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?

Yes

EN

Which materials/guidance are being used

Manual on risk assessment of LMOs developed by the CBD Secretariat ³
Guidance on risk assessment of LMOs developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management ⁴

72. Please use the space below to provide further details on the implementation of Articles 15 and 16 in your country:

The Government of Bangladesh has developed several important documents related to the confined field trials of genetically engineered (GE) crops. These include: - Guidelines for Confined Field Trials of GE Crops - Standard Operating Procedures (SOPs) for Confined Field Trials of GE Crops - Inspectors’ Manual for Confined Field Trials of GE Crops - Data Recording Formats for Confined Field Trials - Guidelines for Safety Assessment of Foods Derived from GE Crops These documents aim to fulfil the necessary requirements for the risk assessment of GE crops. Various aspects of risk assessment and risk management have been incorporated into the Biosafety Guidelines of Bangladesh (2012) and the Biosafety Rules of Bangladesh (2012). While a GMO detection laboratory has been established within the Department of Environment (DoE), there is a need for further development of laboratory facilities to assess the risks associated with living modified organisms (LMOs).

EN

Article 17 – Unintentional transboundary movements⁵ and emergency measures

⁵ In accordance with the operational definition adopted in decision CP-VIII/16, “‘Unintentional transboundary movement’ is a transboundary movement of a living modified organism that has inadvertently crossed the national borders of a Party where the living modified organism was released, and the requirements of Article 17 of the Protocol apply to such transboundary movements only if the living modified organism involved is likely to have significant adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, in the affected or potentially affected States.”

73. Has your country established measures to notify affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations in case of a release under its jurisdiction that leads, or may lead, to an unintentional transboundary movement?

No

EN

74. In the current reporting period, how many releases of LMOs occurred under your country’s jurisdiction that led, or may have led, to an unintentional transboundary movement?

None

EN

75. If you answered under question 74 that a release occurred, has your country notified affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations?

76. In the current reporting period, how many times has your country become aware of an unintentional transboundary movement into its territory?

None

EN

77. Does your country have the capacity to take appropriate measures in response to unintentional transboundary movements?

Yes

EN

78. Please use the space below to provide further details on the implementation of Article 17 in your country:

Bangladesh implements Article 17 by mandating that all authorized firms and institutions develop comprehensive contingency plans and establish dedicated emergency response frameworks. Under Rule 8 of the Biosafety Rules (2012) and Section 2.3.2.2(e) of the 2008 Guidelines, developers must prepare emergency plans for potential accidents or unintentional releases, which are supervised by the Field-level Biosafety Committee (FBC) and Biological Safety Officers (BSO). In the event of an accident, Rule 7 requires the immediate reporting of the situation to the National Committee on Biosafety (NCB), while Rule 6 empowers the Director General to mobilize an inter-agency emergency response by seeking immediate assistance and cooperation from any relevant ministry or department to resolve the problem on an emergency basis.

EN

Article 18 – Handling, transport, packaging and identification

79. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?

Yes

EN

80. Has your country taken measures to require that documentation accompanying LMOs-FFP, in cases where the identity of the LMOs is not known, clearly identifies that they may contain LMOs and are not intended for intentional introduction into the environment, as well as a contact point for further information?

Yes

EN

81. Has your country taken measures to require that documentation accompanying LMOs-FFP, in cases where the identity of the LMOs is known, clearly identifies that they contain LMOs and are not intended for intentional introduction into the environment, as well as a contact point for further information?

Yes

EN

82. If you answered Yes or Yes, to some extent to question(s) 79, 80 and/or 81, what type of documentation accompanying LMOs does your country require?

Documentation specific to LMOs

EN

83. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as LMOs, and specifies any requirements for the safe handling, storage, transport and use, as well as the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?

Yes

EN

84. If you answered Yes or Yes, to some extent to question 83, what type of documentation does your country require for the identification of LMOs that are destined for contained use?

Documentation specific to LMOs

EN

85. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of the Cartagena Protocol applicable to the exporter?

Yes

EN

86. If you answered Yes or Yes, to some extent to question 85, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment?

Documentation specific to LMOs

EN

87. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?

Yes, to some extent:

EN

Additional Information

National Biosafety Committee (NCB) could undertake enforcement of identification and documentation of LMOs.

EN

88. In the current reporting period, how many customs officers in your country have received training in the identification of LMOs?

None

EN

Is this number adequate:

89. Has your country established procedures for the sampling and detection of LMOs?

Yes

EN

90. Does your country have access to and use resource materials and detection methods to detect and identify LMOs?

a. access to resource materials and detection methods to detect and identify LMOs?

Yes

EN

b. use of resource materials and detection methods to detect and identify LMOs?

Yes

EN

91. Does your country have access to and use tools to detect and identify LMOs?

a. access to tools?

Yes

EN

b. use of tools?

Yes

EN

92. Does your country have access to and use certified reference materials necessary to detect and identify LMOs?

a. access to certified reference materials?

Yes

EN

b. use of certified reference materials?

Yes

EN

93. How many laboratory personnel in your country have received training in detection of LMOs?

10 to 49

EN

Is this number adequate:

No

EN

94. Does your country have reliable access to technical infrastructures, such as laboratories for the detection and identification of LMOs?

a. technical infrastructure for detection of LMOs?

Yes

EN

b. technical infrastructure for identification of LMOs

Yes

EN

95. How many laboratories in your country are certified for LMO detection?

None

EN

96. If you answered under question 95 that certified laboratories exist in your country, how many of them are currently operating in the field of the detection of LMOs?

None

EN

97. Please use the space below to provide further details on the implementation of Article 18 in your country:

The requirements for handling, transport, packaging, and identification are integrated into Bangladesh's regulatory framework. The Biosafety Guidelines (2008) and the SOPs for confined field trials include specific norms for these activities. A key challenge is the limited capacity for enforcement, particularly at the border. While a GMO detection laboratory has been established, it requires further strengthening, including accreditation, access to certified.

EN

Article 19 – Competent national authorities and national focal points

98. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?

Not applicable, only one competent national authority was designated

EN

99. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?

Yes, to some extent:

EN

Additional Information

Institutional Biosafety Committee (IBC) and Biosafety Core Committee (BCC) have been assisting National Committee on Biosafety (NCB) to perform the administrative decisions.

EN

100. Has your country undertaken initiatives to strengthen collaboration among national focal points, competent national authority(ies) and other institutions on biosafety-related matters?

Yes

EN

Additional Information

GMO detection lab has been established and some officials received training on GMO detection and good laboratory practices.

EN

101. Please use the space below to provide further details on the implementation of Article 19 in your country:

Bangladesh Govt. has designated one Focal Point as well as Competent National Authority to implement the Article 19. Moreover, provisions are there in the Implementation of multi-country biosafety project for enhancing the capacity of the competent national authority as well as relevant stakeholders.

EN

Article 20 – Information-sharing and the Biosafety Clearing-House (BCH):

102. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available ⁶ and whether it has been submitted to the BCH:

a. Existing legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3(a))

Information available but only partially available in the BCH

EN

b. Legislation, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)

Information available but only partially available in the BCH

EN

c. Bilateral, multilateral and regional agreements and arrangements (Article 14, paragraph 2, and Article 20, paragraph 3 (b))

Information available but not in the BCH

EN

d. Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3(e))

Information available and in the BCH

EN

e. Decisions regarding transit of LMOs (Article 6, paragraph 1)

Information not available

EN

f. Decisions regarding import of LMOs for contained use (Article 6, paragraph 2)

Information available but not in the BCH

EN

g. Notifications regarding the release under your country’s jurisdiction that leads, or may lead, to an unintentional transboundary movement of a LMO that is likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)

Information not available

EN

h. Information concerning cases of illegal transboundary movements of LMOs (Article 25, paragraph 3)

Information not available

EN

i. Decisions regarding the importation of LMOs for intentional introduction into the environment (Article 10, paragraph 3)

Information available but not in the BCH

EN

j. Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)

Information available but not in the BCH

EN

k. Decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)

Information not available

EN

l. Decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with Annex III to the Protocol (Article 11, paragraph 6)

Information available but not in the BCH

EN

m. Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)

Information not available

EN

n. Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)

Information not available

EN

o. Cases where intentional transboundary movement may take place at the same time as the movement is notified to your country (Article 13, paragraph 1(a))

Information not available

EN

p. LMOs exempted from the advance informed agreement procedure (Article 13, paragraph 1(b))

Information not available

EN

q. Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3(c))

Information available but not in the BCH

EN

103. Please provide a brief explanation if you answered that the information is available but not in the BCH or only partially available in the BCH to any item under question 102:

Bangladesh requires additional capacity-building measures, including training for the operation of the Biosafety Clearing House (BCH).

EN

104. Has your country established a mechanism for the coordination among the BCH national focal point, the Cartagena Protocol national focal point, and the competent national authority(ies) for making information available to the BCH?

Yes, to some extent:

EN

Additional Information

Bangladesh has established a coordination mechanism. Sometime limited manpower makes hinder to its effectiveness. To address these issues the Department of Environment has proposed creating a specialized wing named “Biodiversity & Biosafety Wing” to manage biosafety mandates more efficiently.

EN

105. In the current reporting period, has your country used the information available in the BCH in its decision-making processes on LMOs?

Yes, in some cases

EN

106. In the current reporting period, has your country experienced difficulties accessing or using the BCH?

Yes

EN

Additional Information

Problems are prevailing in terms of establishing interconnectivity and giving data inputs to BCH.

EN

107. Does your country have a national biosafety clearing-house?

Yes

EN

Additional Information

https://bchbd.org/

EN

108. Please use the space below to provide further details on the implementation of Article 20 in your country:

The available information is posted in the Biosafety Clearing House. Bangladesh has developed a national biosafety clearing house website that needs further work to become more operational.

EN

Article 21 – Confidential information

109. Has your country established procedures to protect confidential information received under the Protocol?

No

EN

110. Does your country allow the notifier to identify information that is to be treated as confidential?

No

EN

111. Please use the space below to provide further details on the implementation of Article 21 in your country:

Bangladesh implements Article 21 by providing legal and institutional safeguards to protect proprietary data, harmonizing its practices with those of other Parties under the Biosafety Rules (2012) and Guidelines (2008). Specifically, Section 2.1.6.3 (h) of the 2008 Guidelines mandates that the National Committee on Biosafety (NCB) must maintain the confidentiality of information of commercial importance upon a researcher's request.

EN

Article 22 – Capacity-building

112. Does your country have predictable and reliable funding for its capacity-building needs for the effective implementation of the Protocol?

No

EN

113. Has your country received external support for the development and/or strengthening of human resources and institutional capacities in biosafety?

Yes, to some extent:

EN

Additional Information

With financial support from the American Food Safety Institute (AFSI), the South Asian Biosafety Program (SABP) organized a series of training sessions for members of the Biosafety Core Committee (BCC), the Department of Environment (DoE), the Ministry of Environment, Forest and Climate Change (MoEFCC), and other relevant stakeholders on “Origins of biosafety internationally, the relevant policies and regulations in Bangladesh, and the necessary regulatory process during each phase of biotechnology research, development and release”.

EN

114. If you answered Yes or Yes, to some extent to question 113, how was this support made available?

Bilateral channels

115. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?

No

EN

116. If you answered Yes to question 115, how was this support made available?

117. In the current reporting period, has your country used its GEF STAR allocation for biosafety activities?

Yes

EN

Additional Information

Currently, Bangladesh is implementing a multi-country biosafety project that is funded by the GEF STAR allocation.

EN

118. In the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?

Yes, to some extent:

EN

Additional Information

Under the South Asian Biosafety Program, a series of training sessions were organized to strengthen human resource capacities in biosafety.

EN

119. If you answered Yes or Yes, to some extent to question 118, in which of the following areas were these activities undertaken (select all that apply)?

Institutional capacity and human resources
Risk assessment and other scientific and technical expertise
Risk management
Public awareness, participation and education in biosafety
Information exchange and data management, including participation in the Biosafety Clearing-House
Identification of LMOs, including their detection
Taking into account risks to human health

120. If you answered Yes or Yes, to some extent to question 118, did your country use capacity-building materials, including online resources, for the development and/or strengthening of capacity-building?

Yes

EN

121. In the current reporting period, has your country carried out a capacity-building needs assessment?

Yes

EN

122. Does your country still have capacity-building needs?

Yes

EN

123. If you answered Yes to question 122, which of the following areas still need capacity-building (select all that apply)?

Institutional capacity and human resources
Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety)
Risk assessment and other scientific and technical expertise
Risk management
Public awareness, participation and education in biosafety
Information exchange and data management, including participation in the Biosafety Clearing-House
Scientific, technical and institutional collaboration at subregional, regional and international levels
Technology transfer
Sampling, detection and identification of LMOs
Socioeconomic considerations
Implementation of the documentation requirements for handling, transport, packaging and identification
Handling of confidential information
Measures to address unintentional and/or illegal transboundary movements of LMOs
Scientific biosafety research relating to LMOs
Taking into account risks to human health
Liability and redress

124. If you answered Yes to question 122, has your country prioritized its capacity-building needs?

Yes

EN

125. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?

Yes

EN

126. Please use the space below to provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:

Bangladesh needs more capacity in research and development and need risk assessment and risk management training for preventing the adverse situation arising from GMOs. As well as enhance capacity for checkpoint handling.

EN

Article 23 – Public awareness and participation

127. Is biosafety public awareness, education and/or participation addressed in legislation or policy in your country?

Yes, to some extent:

EN

Additional Information

Biosafety policy 2024, guideline 2008, National Biosafety Framework, 2006 has got the element on Public Awareness and Participation.

EN

128. Has your country established a mechanism to ensure public access to information on LMOs?

Yes

EN

Additional Information

Bangladesh has established the Biosafety Clearing House (BCH BD) to ensure public access to information on Living Modified Organisms (LMOs). However, more work is needed to fully operationalize the BCH BD.

EN

129. Has your country established a mechanism to facilitate and promote public participation, including consultation, in the decision-making process regarding LMOs?

Yes, to some extent:

EN

Additional Information

Stakeholder consultation meeting before any environmental release of LMOs.

EN

130. Has your country informed the public about existing modalities for public participation in the decision-making process regarding LMOs?

Yes, to some extent:

EN

Additional Information

In National Biosafety policy and National Biosafety Framework, modalities of public participation was integrated and disseminated.

EN

131. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs?

1 to 4

EN

132. In the current reporting period, has your country made the results of decisions regarding LMOs available to the public?

Yes

EN

133. Has your country informed the public about the means to access the Biosafety Clearing-House?

Yes

EN

134. Has biosafety been addressed or integrated in educational and training programmes in your country?

Yes

EN

135. Does your country have in place a national communication strategy on biosafety?

Yes

EN

Additional Information

In the National Biosafety Framework, Process and Strategy for Public, Education and Awareness is included.

EN

136. Does your country have any awareness and outreach programmes on biosafety?

Yes

EN

Additional Information

Video Documentary and TV Spot Developed and TV Spot Aired in the TV Channels.

EN

137. Does your country currently have a national biosafety website?

Yes

EN

Additional Information

https://www.bchbd.org/

EN

138. In the current reporting period, has your country accessed resource materials for facilitating and promoting public awareness, education and participation in biosafety?

Yes

EN

139. Please use the space below to provide further details on the implementation of Article 23 in your country:

Bangladesh needs to develop structured tools and techniques for public consultation involving wider participation.

EN

Article 24 – Non-Parties

140. Has your country entered into any bilateral, regional, or multilateral agreement(s) with non-Parties regarding transboundary movements of LMOs?

No

EN

141. In the current reporting period, has your country imported LMOs from a non-Party?

No

EN

142. In the current reporting period, has your country exported LMOs to a non-Party?

No

EN

143. If you answered Yes to question 141 and/or 142, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety?

144. Please use the space below to provide further details on the implementation of Article 24 in your country:

To date, Bangladesh has not entered into any bilateral, regional, or multilateral agreements with non-Parties regarding transboundary movements of LMOs.

EN

Article 25 – Illegal transboundary movements ⁷

⁷ In accordance with the operational definition adopted in decision CP-VIII/16, “‘Illegal transboundary movement’ is a transboundary movement of living modified organisms carried out in contravention of the domestic measures to implement the Protocol that have been adopted by the Party concerned”

145. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement the Cartagena Protocol?

Yes

EN

146. In the current reporting period, how many cases of illegal transboundary movements of LMOs has your country become aware of?

None

EN

147. If you indicated under question 146 that your country became aware of cases of illegal transboundary movements, has the origin of the LMO(s) been established?

148. Please use the space below to provide further details on the implementation of Article 25 in your country:

No cases of illegal transboundary movements have been reported or become known to the competent authorities during this reporting period.

EN

Article 26 – Socio-economic considerations

149. Does your country have any specific approaches or requirements that facilitate how socioeconomic considerations should be taken into account in LMO decision-making?

Yes

EN

150. Has your country used resource materials for taking socioeconomic considerations into account?

Yes

EN

151. In the current reporting period, have socioeconomic considerations arising from the impact of LMOs been taken into account in decision-making?

Yes, always

EN

152. Please use the space below to provide further details on the implementation of Article 26 in your country:

Bangladesh implements Article 26 of the Cartagena Protocol by integrating detailed socio-economic research and farmer surveys into the risk assessment process for environmental releases. The institute conducts comparative analyses between traditional and LMOs crops to evaluate how pest-resistant varieties affect household income, production costs, and long-term profitability for local farmers such as during the Bt Cotton release. These assessments specifically address the benefits of rural communities by examining the potential for LMOs to reduce reliance on chemical pesticides and serve as a strategic tool for national poverty alleviation. By incorporating local perceptions of health, environmental safety, and financial stability into its regulatory evaluations.

EN

Article 28 – Financial mechanism and resources

153. In the current reporting period, how much funding (in the equivalent of US dollars) has your country mobilized to support implementation of the Cartagena Protocol beyond the regular national budgetary allocation?

5,000 to 49,999 USD

EN

Article 33 – Monitoring and reporting

Article 33 requires Parties to monitor the implementation of its obligations under the Cartagena Protocol and to report to the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on measures taken to implement the Protocol.

154. Does your country have in place a system to monitor and enforce the implementation of the Cartagena Protocol?

Yes

EN

Cooperation

Goal B.4 of the Implementation Plan for the Cartagena Protocol addresses cooperation and coordination on biosafety issues at the national, regional and international levels. Questions related to this goal are presented below, including questions related to cooperation under different provisions of the Protocol.

155. In the current period, has your country cooperated with other Parties in:

a. exchange of scientific, technical and institutional knowledge;

Yes

EN

b. identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity? (Article 16(5)).

No

EN

c. research and information exchange on any socioeconomics impacts of LMOs? (Article 26(2))

No

EN

Does this include research and information exchange on socioeconomic impacts of LMOs on indigenous peoples and local communities?

d. public awareness, education and participation? (Article 23(1)(a))

Yes

EN

e. strengthening capacities for the implementation of the Protocol?

Yes

EN

156. In the current reporting period, has your country engaged in bilateral, regional or multilateral activities for the implementation of the Protocol?

Yes

EN

157. Does your country have mechanisms in place for involving indigenous peoples and local communities and relevant stakeholders from different sectors in the implementation of the Protocol?

a. mechanisms for involving indigenous peoples and local communities

Yes

EN

b. mechanisms for involving relevant stakeholders from different sectors

Yes

EN

158. Please use the space below to provide further details on biosafety cooperation in your country:

Biosafety cooperation in Bangladesh is implemented through a multi-stakeholder institutional framework led by the National Committee on Biosafety (NCB). This committee includes representatives from various ministries, research institutes, and non-governmental organizations (NGOs). To supporting NCB, Biosafety Core Committee (BCC) works which provides specialized scientific expertise to assist in decision-making and monitoring functions. At the field level, Field-level Biosafety Committees (FBCs) and at the institute level, Institutional Biosafety Committees (IBCs) work closely with local authorities and residents to oversee field activities and respond to emergencies. This collaborative structure, outlined in the 2012 Rules and 2008 Guidelines, ensures that biosafety oversight is a shared responsibility across multiple sectors. It fosters public-private partnerships and inter-agency cooperation to protect both environmental and human health.

EN

Nagoya – Kuala Lumpur Supplementary Protocol on Liability and Redress

Parties to the Cartagena Protocol that are not yet Party to the Supplementary Protocol are also invited to respond to the questions below

159. Is your country a Party to the Nagoya – Kuala Lumpur Supplementary Protocol on Liability and Redress?

No

EN

Is there any national process in place towards becoming a Party to the Supplementary Protocol?

Yes

EN

Additional Information

Bangladesh Biosafety Rules, 2012 and National Biosafety Policy, 2024

EN

160. Has your country introduced the necessary measures for the implementation of the Supplementary Protocol?

National measures are partially in place

EN

161. Which instruments are in place for the implementation of the Supplementary Protocol (select all that apply)?

One or more national laws

Please provide further information on the instruments in place:

Bangladesh Biosafety Rules, 2012 and National Biosafety Policy, 2024

EN

162. Does your country have administrative or legal instruments that require response measures to be taken:

a. In case of damage resulting from LMOs?

Yes

EN

b. In case there is sufficient likelihood that damage will result if response measures are not taken?

Yes

EN

163. If you answered Yes to question 162a, do these instruments impose requirements on an operator (select all that apply)?

Yes, the operator must inform the competent authority of the damage

164. If you answered Yes to question 162a, do these instruments require the operator to take response measures to avoid damage?

Yes

EN

165. If you answered Yes to question 162a or 162b, do these instruments provide for a definition of “operator”?

Yes

EN

166. If you answered Yes to question 165, which of the following could be an ‘operator’ (select all that apply)?

Permit holder
Person who placed the LMO on the market
Developer
Producer
Notifier
Exporter
Importer
Carrier
Supplier

167. Has a competent authority been identified for carrying out the functions set out in the Supplementary Protocol?

No

EN

168. If you answered Yes to question 167, what measures may the competent authority take (select all that apply)?

169. Does your country have measures in place to provide for financial security for damage resulting from LMOs?

No

EN

170. If you answered Yes to question 169, what type of financial security measures are in place (select all that apply)?

171. Does your country have rules and procedures on civil liability that address damage resulting from LMOs, or has such damage been recognized in court rulings (select all that apply)?

Yes, in court rulings

172. Have there been any occurrences of damage resulting from LMOs in your country?

No

EN

173. If you answered Yes to question 172, have response measures been taken?

174. Please use the space below to provide further details on any activities undertaken in your country towards the implementation of the Nagoya – Kuala Lumpur Supplementary Protocol on Liability and Redress:

During the reporting period, Bangladesh has not acceded to the Nagoya–Kuala Lumpur Supplementary Protocol. Nevertheless, Bangladesh applies national legal and administrative frameworks such Bangladesh Biosafety Rules 2012 and National Biosafety Policy 2024 that require prevention, mitigation and remediation of environmental damage, including obligations for applicants/permit holders to undertake control measures and corrective actions where adverse effects are identified. Institutional coordination for biosafety continues through the National Committee on Biosafety (NCB) and relevant competent authorities, supported by technical assessment mechanisms by Biosafety Core Committee (BCC) and permit conditions that may include monitoring, mitigation, and withdrawal/recall obligations.

EN

Other information

175. Please use this field to provide any other information on issues related to national implementation of the Cartagena Protocol and the Supplementary Protocol, including any obstacles or impediments encountered:

Bangladesh will continue its efforts to implement the Biosafety Policy 2024 and the Biosafety Rules 2012 and Guidelines, strengthening the function of the GMO Detection laboratory to support regulations. Establishment of inter-institutional networking for a wider range of safety analysis, training on monitoring, and enforcement of Biosafety Rules. Provide training regularly to relevant government agencies such as border control (customs), quarantine, and inspection facilities, strengthening cooperation and collaboration with the international bodies towards establishing harmonized systems and procedures of biosafety. In addition, with all these activities, Bangladesh will move ahead towards full implementation of NBF and therefore the Cartagena Protocol on Biosafety.

EN

Comments on reporting format

176. Please use this field to provide any information on difficulties that you have encountered in filling in this report, and suggestions for its improvement:

EN

This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.

This document has been updated. This is not the latest published version. Click here to view the latest version of the record.

Comparing version with latest version 1

Quick links

Need help?

THE CONVENTION ON BIOLOGICAL DIVERSITY

Quick Links

Topics

Information

A part of

This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.

This document has been updated. This is not the latest published version. Click here to view the latest version of the record.

Comparing version with latest version 1 Close comparison

Quick links

Need help?

THE CONVENTION ON BIOLOGICAL DIVERSITY

Quick Links

Topics

Information

A part of

Comparing version with latest version 1